Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Treatment Naive
Eligibility Criteria
Inclusion Criteria: HIV-infected Have never taken ARV drugs CD4 count of 200 cells/mm3 or less within 30 days of study entry if asymptomatic OR CD4 count of 350 cells/mm3 or less within 60 days of study entry if CDC Category A or B clinical condition present OR clinical diagnosis of AIDS, regardless of CD4 count Willing to stay in the study area for the duration of the study Willing to use acceptable forms of contraception Exclusion Criteria: HIV-2 infected Systemic chemotherapy (except interferon) within 6 months prior to study entry Current drug or alcohol abuse that, in the opinion of the investigator, may interfere with the study Serious illness, including any active AIDS-defining infection, active tuberculosis, malaria, or any illness requiring systemic treatment or hospitalization. People who have completed therapy or are clinically stable on therapy for at least 14 days prior to study entry are not excluded. Serious psychiatric problems within 60 days of study entry, including depression, suicidal thoughts or attempts, aggressive behavior, or psychosis-like symptoms Have taken certain medications within 30 days of study entry Pregnancy or breastfeeding
Sites / Locations
- Centre National Hospitalier de Fann, Dakar CIPRA CRS
- Institut d'Hygiène Sociale, Dakar CIPRA CRS
Arms of the Study
Arm 1
Experimental
1
All participants will be given an ARV regimen of lamivudine/zidovudine and efavirenz at study entry. If toxicity or treatment failure occurs, some participants may require changes in their ARV regimens.